Latest Advances in Lung Adenocarcinoma

home / peer-exchange / nsclc9-advances
Lung Cancer Molecular Testing

EP. 1: Lung Cancer Molecular Testing

July 19th 2016
The Importance of Comprehensive Genomic Profiling

EP. 2: The Importance of Comprehensive Genomic Profiling

July 19th 2016
The Emergence of Liquid Biopsy in Lung Cancer

EP. 3: The Emergence of Liquid Biopsy in Lung Cancer

July 19th 2016
Molecular Testing in Squamous Cell Tumors

EP. 4: Molecular Testing in Squamous Cell Tumors

July 19th 2016
Refining Use of EGFR TKIs, Adding Bevacizumab

EP. 5: Refining Use of EGFR TKIs, Adding Bevacizumab

July 19th 2016
TKIs for EGFR Del19 and Beyond Progression

EP. 6: TKIs for EGFR Del19 and Beyond Progression

July 19th 2016

EP. 7: Osimertinib for the T790M Resistance Mutation

July 19th 2016

EP. 8: EGFR TKI Sequencing

July 19th 2016
ALK-Positive NSCLC

EP. 9: ALK-Positive NSCLC

July 19th 2016
Treatment Approaches in Non-Driver Adenocarcinoma

EP. 10: Treatment Approaches in Non-Driver Adenocarcinoma

July 19th 2016
Progression in Non-Driver Adenocarcinoma

EP. 11: Progression in Non-Driver Adenocarcinoma

July 19th 2016
Up-front Treatment Options for Squamous NSCLC

EP. 12: Up-front Treatment Options for Squamous NSCLC

July 19th 2016
The Role of Immunotherapy in Metastatic NSCLC

EP. 13: The Role of Immunotherapy in Metastatic NSCLC

July 19th 2016
Managing Toxicity in Immunotherapy for Lung Cancer

EP. 14: Managing Toxicity in Immunotherapy for Lung Cancer

July 19th 2016
Immunotherapy for Brain Metastases

EP. 15: Immunotherapy for Brain Metastases

July 19th 2016
PD-L1 Biomarker Testing

EP. 16: PD-L1 Biomarker Testing

July 19th 2016
Emerging Biomarkers for Lung Cancer

EP. 17: Emerging Biomarkers for Lung Cancer

July 19th 2016
What is on the Horizon for Immunotherapy in NSCLC?

EP. 18: What is on the Horizon for Immunotherapy in NSCLC?

July 19th 2016
Final Thoughts on NSCLC

EP. 19: Final Thoughts on NSCLC

July 19th 2016